Affinage

OLFM4

Olfactomedin-4 · UniProt Q6UX06

Length
510 aa
Mass
57.3 kDa
Annotated
2026-06-10
63 papers in source corpus 27 papers cited in narrative 27 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

OLFM4 is a secreted olfactomedin-domain glycoprotein expressed in mature neutrophils, intestinal and epithelial tissues, and additional sites including kidney and brown adipose tissue, where it acts broadly as an antiapoptotic, pro-survival, and immunomodulatory factor (PMID:14962908, PMID:23908114, PMID:31304451). Its transcription is driven directly by NF-κB binding to the proximal promoter, induced downstream of G-CSF via a PI3K/ROS/ERK1/2 cascade in myeloid precursors, and is strictly dependent on PU.1 in myeloid cells; in epithelium it is synergistically induced by Notch and TNF-α/NF-κB signaling (PMID:14962908, PMID:18764868, PMID:19908244, PMID:33490652). A core survival mechanism is OLFM4-mediated inhibition of GRIM-19, which de-represses STAT3 activation to suppress apoptosis and promote cell cycle progression, as established by epistatic double-knockdown experiments (PMID:15059901, PMID:31304451). In neutrophils, OLFM4 is a specific-granule protein released through NET formation, and its acidic charge interferes with neutrophil cationic protein oligomerization, dampening bacterial killing and TLR9 activation; accordingly, Olfm4 deletion enhances intracellular killing of S. aureus by elevating cathepsin C, neutrophil elastase, and cathepsin G activity (PMID:23922742, PMID:23908114, PMID:39396234). OLFM4 governs neutrophil cytoskeletal polarization and migration through the RhoA/ROCK1/pMLC2/MYH9 axis (PMID:42034613). Through direct binding partners it controls diverse programs: an OLFM4-MYH9 complex accelerates GSK3β ubiquitination to elevate β-catenin and drive intestinal metaplasia (PMID:38849840); an OLFM4-MTDH complex sustains p38/RORγt signaling to promote IL-22⁺ILC3-mediated intestinal inflammation (PMID:39075283); secreted OLFM4 binds the FAT1 extracellular domain to disrupt FAT1-MST1 coupling and activate YAP (PMID:39627192); and in brown adipose tissue OLFM4 traps the BMP inhibitor Noggin to liberate BMP7-BMPR1B signaling that maintains Schwann cell differentiation and thermogenic innervation (PMID:40467585). OLFM4 additionally binds LGALS3 on PMN-MDSCs to activate NF-κB/PTGS2 and shape inflammatory and tumor-promoting myeloid responses (PMID:35487976, PMID:38613883).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 2004 Medium

    Established the first molecular partner and a survival function by showing OLFM4 binds GRIM-19 to blunt apoptosis and accelerate tumor growth, defining its antiapoptotic role.

    Evidence Reciprocal Co-IP, apoptosis assays, and syngeneic tumor transplantation in murine prostate tumor cells

    PMID:15059901

    Open questions at the time
    • Did not resolve how GRIM-19 inhibition propagates to downstream effectors
    • Binding interface not mapped
  2. 2004 High

    Defined the transcriptional and tissue identity of OLFM4 as a secreted myeloid glycoprotein under strict PU.1 control, anchoring it in neutrophil biology.

    Evidence PU.1-deficient mouse model, promoter-reporter assays, and subcellular fractionation

    PMID:14962908

    Open questions at the time
    • Functional consequence of granule storage not addressed
    • Downregulation in peripheral neutrophils unexplained mechanistically
  3. 2010 High

    Established NF-κB as a direct transcriptional driver of OLFM4 and linked this to G-CSF/PI3K/ROS/ERK signaling and an antiapoptotic phenotype, unifying upstream regulation across myeloid and cancer contexts.

    Evidence EMSA, ChIP, promoter mutagenesis, pharmacological epistasis, and loss/gain-of-function apoptosis assays in CD34+ and gastric cancer cells

    PMID:18764868 PMID:19908244

    Open questions at the time
    • How NF-κB induction integrates with PU.1 dependence unresolved
    • Antiapoptotic effector pathway downstream not defined here
  4. 2013 High

    Resolved OLFM4's neutrophil localization and unconventional release, and showed its deletion enhances bacterial killing via increased cathepsin/protease activity, establishing it as a brake on antimicrobial function.

    Evidence Specific-granule immunolocalization, NET vs degranulation assays, and Olfm4-knockout/CGD mouse infection models with protease activity measurements

    PMID:23908114 PMID:23922742

    Open questions at the time
    • Direct molecular target restraining protease activity not identified in this work
    • Selectivity for S. aureus over A. fumigatus unexplained
  5. 2019 Medium

    Confirmed the OLFM4→GRIM-19→STAT3 axis by epistasis and tied OLFM4 to LGR5-Wnt induction, generalizing the antiapoptotic mechanism to hepatocellular carcinoma.

    Evidence Single and double siRNA knockdown, STAT3 activation assays, and patient tissue correlation

    PMID:31304451

    Open questions at the time
    • Direct biochemical mechanism of GRIM-19 inhibition not shown
    • Whether secreted or intracellular OLFM4 mediates the effect unclear
  6. 2021 Medium

    Identified LGALS3 as a binding partner linking OLFM4 to NF-κB/PTGS2 in PMN-MDSCs, extending its role into myeloid immunosuppression and colitis-associated cancer.

    Evidence Myeloid-specific Olfm4-knockout mice, OLFM4-LGALS3 binding assay, and tumor progression models

    PMID:35487976

    Open questions at the time
    • Binding stoichiometry and interface unresolved
    • Whether LGALS3 acts as a receptor not formally shown
  7. 2024 High

    Provided a biophysical mechanism for OLFM4's antimicrobial restraint, showing its negative charge blocks neutrophil cationic protein oligomerization and TLR9 activation.

    Evidence Charge/structural analysis, in vitro reconstitution of NCP oligomerization, bacterial killing, and TLR9 activation assays

    PMID:39396234

    Open questions at the time
    • Specific NCP species targeted not exhaustively enumerated
    • In vivo relevance to infection outcomes partially addressed
  8. 2024 Medium

    Defined OLFM4 binding partners that drive distinct disease programs: MYH9 (Wnt/β-catenin via GSK3β ubiquitination), MTDH (p38/RORγt in ILC3), and FAT1 (YAP activation), demonstrating partner-dependent pleiotropy.

    Evidence Co-IP of OLFM4 with MYH9, MTDH, and FAT1; ubiquitination, pathway, and knockout/organoid assays across intestinal metaplasia, ILC3 inflammation, and EBV-driven models

    PMID:38849840 PMID:39075283 PMID:39627192

    Open questions at the time
    • Whether one OLFM4 conformation or pool serves all partners unknown
    • Structural basis of partner selectivity not determined
  9. 2025 High

    Revealed an organ-specific extracellular mechanism in which BAT-secreted OLFM4 sequesters Noggin to liberate BMP7-BMPR1B signaling, maintaining Schwann cell differentiation and thermogenic innervation.

    Evidence Olfm4-knockout mice, OLFM4-Noggin binding assay, BMP7-BMPR1B and MEK/ERK pathway analysis with pharmacological rescue, and thermogenesis measurement

    PMID:40467585

    Open questions at the time
    • Whether Noggin-trapping operates in other OLFM4-expressing tissues untested
    • Quantitative affinity for Noggin not reported
  10. 2026 High

    Placed OLFM4 in neutrophil cytoskeletal control, showing it suppresses RhoA/ROCK1/pMLC2 signaling and mislocalizes MYH9 to impair migration, linking its overexpression to defective neutrophil function.

    Evidence Myeloid-specific Rpsa-knockout mice, adoptive transfer, OLFM4 overexpression, pathway and MYH9 localization imaging, validated in sepsis patient neutrophils

    PMID:42034613

    Open questions at the time
    • Direct molecular target through which OLFM4 inhibits RhoA signaling not identified
    • Relationship to the metaplasia OLFM4-MYH9 complex unexplored

Open questions

Synthesis pass · forward-looking unresolved questions
  • How a single secreted glycoprotein selects among its many binding partners (GRIM-19, MYH9, MTDH, FAT1, Noggin, LGALS3) in a tissue- and context-specific manner remains unresolved.
  • No structural model of OLFM4 partner interfaces
  • No unifying determinant of secreted vs intracellular activity
  • Receptor(s) for secreted OLFM4 incompletely defined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0005198 structural molecule activity 2 GO:0098772 molecular function regulator activity 2 GO:0140096 catalytic activity, acting on a protein 2 GO:0140313 molecular sequestering activity 2
Localization
GO:0005576 extracellular region 3 GO:0005829 cytosol 2 GO:0031410 cytoplasmic vesicle 1
Pathway
R-HSA-168256 Immune System 4 R-HSA-162582 Signal Transduction 3 R-HSA-5357801 Programmed Cell Death 3 R-HSA-74160 Gene expression (Transcription) 3
Partners
ARL6IP1FAT1GRIM-19LGALS3MTDHMYH9NOGGIN

Evidence

Reading pass · 27 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2004 GW112 (OLFM4) physically associates with GRIM-19, and this interaction attenuates GRIM-19-mediated retinoic acid/IFN-β-induced cellular apoptosis and apoptosis-related gene expression; forced overexpression of GW112 in murine prostate tumor cells led to more rapid tumor formation in a syngeneic host. Co-immunoprecipitation (binding to GRIM-19), functional apoptosis assays, syngeneic tumor transplantation Cancer Research Medium 15059901
2004 pDP4 (OLFM4) expression in myeloid cells is strictly dependent on the transcription factor PU.1, which binds to a functional site within the pDP4 promoter; the protein is a secreted 57-kDa glycoprotein predominantly expressed in mature neutrophils in bone marrow but markedly downregulated in peripheral blood and peritoneal neutrophils. PU.1-deficient mouse model, promoter-reporter assays, Western blot, subcellular fractionation/immunolocalization Blood High 14962908
2008 G-CSF-induced OLFM4 expression in myeloid precursor cells is regulated by NF-κB binding to the OLFM4 proximal promoter; this induction is mediated through the PI3K-driven ROS→ERK1/2 MAPK pathway, and mutation of the NF-κB binding site in the promoter abolished transcription factor binding and OLFM4 expression. Promoter deletion/mutation reporter assays, EMSA, ChIP, pharmacological inhibitors (PI3K, ERK, ROS scavenger NAC), G-CSF stimulation of human CD34+ cells British Journal of Haematology High 18764868
2010 NF-κB directly regulates GW112 (OLFM4) gene transcription by binding to a site between -442 and -430 of the GW112 promoter; knockdown or overexpression of GW112 in gastric cancer cells demonstrates it confers an antiapoptotic property against cytotoxic agent-induced apoptosis. Serial promoter deletion constructs, EMSA, ChIP, overexpression/siRNA knockdown in gastric cancer cell lines, apoptosis assays Molecular Carcinogenesis High 19908244
2012 OLFM4 knockdown in gastric cancer cells (SGC-7901, MKN45) by RNA interference significantly inhibits tumorigenicity in vitro and in vivo by inducing G1 cell cycle arrest, and sensitizes cells to H2O2- or TNF-α-induced apoptosis through a caspase-3-dependent mechanism (reversed by Z-VAD-fmk). siRNA knockdown, cell proliferation/anchorage-independent growth assays, flow cytometry cell cycle analysis, caspase-3 activity assay, Z-VAD-fmk rescue, xenograft in vivo tumorigenicity Journal of Biomedical Science Medium 22471589
2013 OLFM4 is a neutrophil granule protein localized to specific granules; OLFM4+ and OLFM4− neutrophil subsets are recruited equally to inflammatory sites in vivo; OLFM4 is released extracellularly through NET formation (not conventional degranulation), where it is detected in only a subset of NETs. Immunofluorescence localization to specific granules, in vivo transmigration models (acute experimental inflammation and pathological joint inflammation), NET formation assays, degranulation assays PloS One Medium 23922742
2013 Olfm4 deletion enhances intracellular killing and in vivo clearance of Staphylococcus aureus and improves resistance to S. aureus sepsis in CGD mice; the mechanism involves increased activity of cathepsin C and its downstream proteases (neutrophil elastase and cathepsin G) and elevated inflammatory cytokines; Olfm4 deletion did not enhance defense against Aspergillus fumigatus. Olfm4-knockout mouse model, CGD double-knockout model, intracellular bacterial killing assays, in vivo challenge/clearance, cathepsin C/elastase/cathepsin G activity assays, cytokine measurement Journal of Clinical Investigation High 23908114
2016 OLFM4 knockdown in gastric cancer cells promotes cell migration through activating the NF-κB/interleukin-8 axis; a negative correlation between OLFM4 and IL-8 expression was confirmed in early gastric cancer tumor samples. siRNA knockdown, cell migration assays, NF-κB/IL-8 pathway analysis, immunohistochemistry on patient samples Oncogenesis Medium 27294866
2016 Estrogen receptor α (ERα) signaling induces OLFM4 expression in ovarian cancer cells in an ERα-dependent manner; miR-486-5p targets OLFM4 and decreases its mRNA expression; estrogen treatment reduces cellular miR-486-5p levels, thus relieving OLFM4 suppression; OLFM4 knockdown enhances proliferation, migration, and invasion of ovarian cancer cells. E2 treatment with ERα-dependent reporter assays, miR-486-5p mimic transfection, qRT-PCR, siRNA knockdown, proliferation/migration/invasion assays Oncotarget Medium 26871282
2019 OLFM4 inhibits GRIM-19 expression in hepatocellular carcinoma cells, leading to enhanced STAT3 activation, increased cell cycle progression, and reduced apoptosis; double knockdown of GRIM-19 and OLFM4 restores STAT3 activation, confirming the OLFM4→GRIM-19→STAT3 axis; OLFM4 is also induced by LGR5-Wnt signaling in HCC cells. siRNA knockdown (single and double knockdown), STAT3 activation assays, cell cycle/apoptosis analysis, correlation analysis in 111 HCC patient specimens, in vitro LGR5 overexpression Hepatology Communications Medium 31304451
2019 OLFM4 overexpression inhibits EMT, migration, and invasion in cervical cancer cells through interference with mTOR signaling; pharmacological activation of mTOR by phosphatidic acid largely reverses the suppressive effects of OLFM4 on migration and invasion. OLFM4 overexpression, mTOR pathway inhibition/activation with phosphatidic acid, migration/invasion assays, Western blot for EMT markers Oncology Research Low 30764901
2019 OLFM4 expression in NSCLC cells is upregulated under hypoxia, and OLFM4 is a positive regulator of HIF-1α protein levels; depletion of OLFM4 under hypoxia reduces N-cadherin and vimentin while increasing E-cadherin (blocking EMT), and sensitizes cells to cisplatin. siRNA knockdown under hypoxic conditions, Western blot for HIF-1α and EMT markers, invasion assays, cisplatin sensitivity assays Journal of Cellular Physiology Low 30680718
2020 In juvenile septic mice, OLFM4 is expressed in the kidney (localized to the loop of Henle); OLFM4-null pups show significantly increased survival, reduced renal cell apoptosis, and reduced plasma creatinine after sepsis induction; bone marrow transplant experiments indicate that increased kidney OLFM4 reflects local renal production rather than filtration from plasma. OLFM4-null mouse model, cecal ligation/puncture sepsis model, immunohistochemistry, creatinine measurement, apoptosis assay, bone marrow transplantation American Journal of Physiology - Renal Physiology Medium 32068457
2021 Notch and TNF-α signaling synergistically upregulate OLFM4 transcription in intestinal epithelial cells (confirmed by luciferase reporter assay); this synergy promotes cytoplasmic accumulation of OLFM4 protein, which has antiapoptotic properties; patient-derived tissues and organoids confirmed cytoplasmic OLFM4 accumulation in response to NF-κB and Notch activation. Luciferase reporter assay, TNF-α and Notch pathway stimulation, immunofluorescence/immunohistochemistry, patient-derived organoids Biochemistry and Biophysics Reports Medium 33490652
2021 OLFM4 in PMN-MDSCs mediates NF-κB/PTGS2 pathway activation through binding to LGALS3 (galectin-3, expressed on PMN-MDSCs); mice lacking OLFM4 in myeloid cells show poor PMN-MDSC recruitment, impaired intestinal homeostasis, and delayed colitis-to-colorectal cancer development, with increased response to anti-PD1 therapy. Myeloid-specific Olfm4-knockout mice, co-immunoprecipitation/binding assay (OLFM4-LGALS3 interaction), PMN-MDSC quantification, NF-κB/PTGS2 pathway analysis, tumor progression models Oncogene Medium 35487976
2021 OLFM4 knockdown in rheumatoid arthritis fibroblast-like synoviocytes (FLS) under TNF-α stimulation inhibits FLS proliferation and decreases expression of CXCL9, CXCL11, and MMP-1, indicating OLFM4 promotes inflammatory signaling in FLS. siRNA knockdown in primary FLS under cytokine stimulation, proliferation assays, gene expression analysis Journal of Proteome Research Low 34496567
2021 OLFM4-RET fusion protein induces cellular transformation in HEK293 cells and blocks RET-inhibition of colony growth; expression of OLFM4-RET activates the RAS-RAF-MAPK and STAT3 signaling pathways; targeted expression in mouse small intestine leads to hyperplasia, adenoma, or adenocarcinoma. Cellular transformation assay, colony growth assay, pathway activation (Western blot), transgenic mouse model Oncogene Medium 34675408
2021 OLFM4 depletion in gallbladder cancer cells reduces ARL6IP1 expression and sensitizes cells to cisplatin both in vitro and in vivo; the mechanism involves CDDP-induced increase in Bax and Bad expression and caspase-3 cascade activation in OLFM4-depleted cells via ARL6IP1. siRNA knockdown, in vitro cisplatin resistance assays, in vivo xenograft, Western blot for apoptosis markers (Bax, Bad, caspase-3) Translational Oncology Medium 34974280
2021 OLFM4 regulates lung epithelial cell pro-inflammatory responses in sepsis-related ARDS by modulating the LDHA phosphorylation/ROS/HIF-1α/NF-κB axis; OLFM4 overexpression and recombinant OLFM4 treatment suppressed LPS-induced NF-κB activation in lung epithelial cells by reducing ROS production and HIF-1α expression. OLFM4 overexpression, recombinant OLFM4 treatment, LPS stimulation, ROS measurement, Western blot for pLDHA/HIF-1α/NF-κB, CLP sepsis mouse model, immunofluorescence co-localization Journal of Inflammation Research Medium 34955649
2024 OLFM4 is a negatively charged secreted neutrophil granule protein that inhibits neutrophil cationic protein (NCP) oligomerization through charge-based interference; this inhibition blocks neutrophil-mediated bacterial killing and TLR9 activation in plasmacytoid dendritic cells and neutrophils via DNA complex formation; OLFM4 inhibition enhances neutrophil-dependent bacterial killing, DNA complex formation, and accelerates skin wound closure. Structural/biophysical analysis of charge properties, OLFM4 addition/inhibition assays for NCP oligomerization, bacterial killing assays, TLR9 activation assays in pDCs and neutrophils, wound closure assays Cell Reports High 39396234
2024 OLFM4 promotes ILC3-mediated intestinal inflammation by acting as a positive regulator of IL-22+ILC3; OLFM4 deficiency reduces IL-22 production by ILC3 through ASK1-p38 MAPK signaling-dependent downregulation of RORγt protein; the OLFM4-metadherin (MTDH) complex upregulates p38/RORγt signaling necessary for IL-22+ILC3 activation. OLFM4-knockout mice (full and RORγt-specific conditional), co-immunoprecipitation (OLFM4-MTDH complex), p38 MAPK/RORγt pathway analysis, IL-22 production assays, bacterial infection challenge Communications Biology Medium 39075283
2024 EBV infection activates the cGAS-STING pathway and increases OLFM4 expression; OLFM4 is secreted via large microvesicles (MVs) and binds the extracellular cadherin domain of FAT1, impairing FAT1's intracellular interaction with MST1 and leading to YAP activation in recipient cells. EV/MV proteomics, cGAS-STING pathway inhibition/activation, co-immunoprecipitation (OLFM4-FAT1 extracellular domain; FAT1-MST1 intracellular interaction), YAP reporter assays Nature Communications High 39627192
2024 OLFM4 promotes intestinal metaplasia progression by binding MYH9 (Myosin heavy chain 9), which together accelerates the ubiquitination of GSK3β, resulting in increased β-catenin levels through the Wnt signaling pathway and promoting cell proliferation and invasion. Co-immunoprecipitation (OLFM4-MYH9 interaction), GSK3β ubiquitination assay, β-catenin/Wnt pathway analysis, PLGC cell models, animal models, organoids Molecular Cancer Medium 38849840
2024 Galectin-3 (Gal-3) stimulates OLFM4-mediated secretion of growth-promoting factors (GPFs) by placental PMN-MDSCs; GPF regulation via OLFM4 in placental PMN-MDSCs is mediated through HIF-1α; myeloid-specific Olfm4 knockout in female mice causes FGR during pregnancy with decreased placental PMN-MDSC populations and offspring intestinal inflammation. Myeloid-specific Olfm4-knockout mice, galectin-3 stimulation assays, HIF-1α pathway analysis, single-cell transcriptomics of placental PMN-MDSCs, GPF secretion assays International Immunopharmacology Medium 38613883
2025 BAT-secreted OLFM4 traps Noggin (an endogenous BMP inhibitor), thereby liberating BMP7-BMPR1B signaling to promote Schwann cell differentiation; loss of Olfm4 in BAT reduces BMP7 signaling in mature Schwann cells, triggering MEK/ERK-dependent dedifferentiation, which impairs both sensory and sympathetic innervation of BAT and reduces thermogenesis. Olfm4-knockout mouse model, co-immunoprecipitation/binding assay (OLFM4-Noggin interaction), BMP7-BMPR1B pathway analysis, Schwann cell differentiation assays, MEK/ERK inhibition rescue, thermogenesis measurement Nature Communications High 40467585
2026 RPSA deficiency induces overexpression of OLFM4 in neutrophils; elevated OLFM4 inhibits activation of the RhoA/ROCK1/pMLC2 signaling pathway, reduces MYH9 expression, and causes aberrant MYH9 translocation from the uropod to the cytosol in migrating neutrophils, disrupting cytoskeletal polarization and uropod extension to abrogate neutrophil migratory function. Myeloid-specific Rpsa-knockout mice, adoptive cell transfer, neutrophil depletion, OLFM4 overexpression, RhoA/ROCK1/pMLC2 pathway analysis, MYH9 localization by imaging, migration assays Nature Communications High 42034613
2024 ARL6IP1 physically interacts with OLFM4 in breast cancer cells (confirmed by Co-IP); OLFM4 overexpression partially counteracts the suppression of glycolysis and pro-tumorigenic cell behavior caused by ARL6IP1 knockdown, placing OLFM4 downstream of ARL6IP1 in a glycolysis-regulatory axis. Co-immunoprecipitation (ARL6IP1-OLFM4 interaction), siRNA knockdown, OLFM4 overexpression rescue, Seahorse metabolic flux assay (ECAR, OCR), cell proliferation/invasion/migration assays Combinatorial Chemistry & High Throughput Screening Low 40444622

Source papers

Stage 0 corpus · 63 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 180 21415212
2004 GW112, a novel antiapoptotic protein that promotes tumor growth. Cancer research 118 15059901
2014 Robust cre-mediated recombination in small intestinal stem cells utilizing the olfm4 locus. Stem cell reports 97 25254337
2013 The human neutrophil subsets defined by the presence or absence of OLFM4 both transmigrate into tissue in vivo and give rise to distinct NETs in vitro. PloS one 93 23922742
2009 Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. International journal of cancer 88 19670418
2001 Upregulation of Reg 1alpha and GW112 in the epithelium of inflamed colonic mucosa. Gut 86 11302958
2007 Specific overexpression of OLFM4(GW112/HGC-1) mRNA in colon, breast and lung cancer tissues detected using quantitative analysis. Cancer science 67 17270020
2013 Olfm4 deletion enhances defense against Staphylococcus aureus in chronic granulomatous disease. The Journal of clinical investigation 53 23908114
2019 LncRNA MIR503HG inhibits cell migration and invasion via miR-103/OLFM4 axis in triple negative breast cancer. Journal of cellular and molecular medicine 50 31062436
2012 Depletion of OLFM4 gene inhibits cell growth and increases sensitization to hydrogen peroxide and tumor necrosis factor-alpha induced-apoptosis in gastric cancer cells. Journal of biomedical science 46 22471589
2010 Up regulation of GW112 Gene by NF kappaB promotes an antiapoptotic property in gastric cancer cells. Molecular carcinogenesis 46 19908244
2017 OLFM4, KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early colorectal cancer stages. Clinical proteomics 45 28344541
2011 Overexpression of S100B, TM4SF4, and OLFM4 genes is correlated with liver metastasis in Taiwanese colorectal cancer patients. DNA and cell biology 42 22011044
2008 The regulation of OLFM4 expression in myeloid precursor cells relies on NF-kappaB transcription factor. British journal of haematology 42 18764868
2021 OLFM4 Regulates Lung Epithelial Cell Function in Sepsis-Associated ARDS/ALI via LDHA-Mediated NF-κB Signaling. Journal of inflammation research 41 34955649
2018 OLFM4, LY6D and S100A7 as potent markers for distant metastasis in estrogen receptor-positive breast carcinoma. Cancer science 40 30137688
2014 Association study of common polymorphisms in MSRA, TFAP2B, MC4R, NRXN3, PPARGC1A, TMEM18, SEC16B, HOXB5 and OLFM4 genes with obesity-related traits among Portuguese children. Journal of human genetics 34 24670271
2016 Estrogen receptor-mediated miR-486-5p regulation of OLFM4 expression in ovarian cancer. Oncotarget 32 26871282
2004 pDP4, a novel glycoprotein secreted by mature granulocytes, is regulated by transcription factor PU.1. Blood 29 14962908
2024 OLFM4 promotes the progression of intestinal metaplasia through activation of the MYH9/GSK3β/β-catenin pathway. Molecular cancer 28 38849840
2018 Identification of cells expressing OLFM4 and LGR5 mRNA by in situ hybridization in the yolk sac and small intestine of embryonic and early post-hatch chicks. Poultry science 27 29155957
2021 Comparative Analysis of Patient-Matched PDOs Revealed a Reduction in OLFM4-Associated Clusters in Metastatic Lesions in Colorectal Cancer. Stem cell reports 26 33711267
2019 Blocking OLFM4/HIF-1α axis alleviates hypoxia-induced invasion, epithelial-mesenchymal transition, and chemotherapy resistance in non-small-cell lung cancer. Journal of cellular physiology 26 30680718
2016 Loss of OLFM4 promotes tumor migration through inducing interleukin-8 expression and predicts lymph node metastasis in early gastric cancer. Oncogenesis 25 27294866
2019 OLFM4 Enhances STAT3 Activation and Promotes Tumor Progression by Inhibiting GRIM19 Expression in Human Hepatocellular Carcinoma. Hepatology communications 24 31304451
2021 Notch and TNF-α signaling promote cytoplasmic accumulation of OLFM4 in intestinal epithelium cells and exhibit a cell protective role in the inflamed mucosa of IBD patients. Biochemistry and biophysics reports 23 33490652
2022 OLFM4 deficiency delays the progression of colitis to colorectal cancer by abrogating PMN-MDSCs recruitment. Oncogene 21 35487976
2016 miR-590 accelerates lung adenocarcinoma migration and invasion through directly suppressing functional target OLFM4. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 21 28012926
2019 OLFM4 Expression in Ductal Carcinoma In Situ and in Invasive Breast Cancer Cohorts by a SWATH-Based Proteomic Approach. Proteomics 20 31318138
2020 Juvenile OLFM4-null mice are protected from sepsis. American journal of physiology. Renal physiology 19 32068457
2021 Quantitative Proteomic Analysis of Synovial Tissue Reveals That Upregulated OLFM4 Aggravates Inflammation in Rheumatoid Arthritis. Journal of proteome research 18 34496567
2024 Epstein-Barr virus infection upregulates extracellular OLFM4 to activate YAP signaling during gastric cancer progression. Nature communications 17 39627192
2024 OLFM4 modulates intestinal inflammation by promoting IL-22+ILC3 in the gut. Communications biology 15 39075283
2021 Overexpression of Cancer-Associated Stem Cell Gene OLFM4 in the Colonic Epithelium of Patients With Primary Sclerosing Cholangitis. Inflammatory bowel diseases 15 33570127
2021 Super-enhancer-associated long noncoding RNA AC005592.2 promotes tumor progression by regulating OLFM4 in colorectal cancer. BMC cancer 15 33622275
2021 OLFM4 depletion sensitizes gallbladder cancer cells to cisplatin through the ARL6IP1/caspase-3 axis. Translational oncology 13 34974280
2019 OLFM4 Inhibits Epithelial-Mesenchymal Transition and Metastatic Potential of Cervical Cancer Cells. Oncology research 12 30764901
2015 Plasma levels of OLFM4 in normals and patients with gastrointestinal cancer. Journal of cellular and molecular medicine 11 26416558
2021 OLFM4-RET fusion is an oncogenic driver in small intestine adenocarcinoma. Oncogene 9 34675408
2024 Paneth-like cells produced from OLFM4+ stem cells support OLFM4+ stem cell growth in advanced colorectal cancer. Communications biology 8 38182890
2022 Qinbaohong Zhike Oral Liquid Attenuates LPS-Induced Acute Lung Injury in Immature Rats by Inhibiting OLFM4. Oxidative medicine and cellular longevity 8 36035204
2023 CD115- monocytic myeloid-derived suppressor cells are precursors of OLFM4high polymorphonuclear myeloid-derived suppressor cells. Communications biology 7 36922564
2022 New Insights of OLFM2 and OLFM4 in Gut-Liver Axis and Their Potential Involvement in Nonalcoholic Fatty Liver Disease. International journal of molecular sciences 7 35806447
2019 Olfactomedin 4 (OLFM4) expression is associated with nodal metastases in esophageal adenocarcinoma. PloS one 7 31283789
2015 Expression of GW112 and GRIM-19 in colorectal cancer tissues. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 7 26011333
2025 AntagomiR-192-5p-engineered exosomes encapsulated in MXene-modified GelMA hydrogel facilitated epithelization of burn wounds by targeting OLFM4. Bioactive materials 6 40575328
2024 Blocking OLFM4/galectin-3 axis in placental polymorphonuclear myeloid-derived suppressor cells triggers intestinal inflammation in newborns. International immunopharmacology 6 38613883
2024 OLFM4 regulates the antimicrobial and DNA binding activity of neutrophil cationic proteins. Cell reports 6 39396234
2024 Refining the diagnostic utility of OLFM4 in gastric cancer precursors: a call for rigorous methodologies. Molecular cancer 5 39118167
2021 Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC. Canadian journal of gastroenterology & hepatology 5 34912753
2020 OLFM4 polymorphisms predict septic shock survival after major surgery. European journal of clinical investigation 5 32996122
2024 Dendritic cells pulsed with penetratin-OLFM4 inhibit the growth and metastasis of melanoma in mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 4 38968793
2024 Knockdown of OLFM4 protects cardiomyocytes from sepsis by inhibiting apoptosis and inflammatory responses. Allergologia et immunopathologia 4 39278846
2022 Increased expression of OLFM4 and lysozyme during necrotizing enterocolitis in neonates: an observational research study. BMC pediatrics 3 35410162
2025 The Association of OLFM4 with the Progression and Cisplatin Resistance of Head and Neck Squamous Carcinoma. Current oncology (Toronto, Ont.) 2 40422535
2025 Brown adipose tissue secretes OLFM4 to coordinate sensory and sympathetic innervation via Schwann cells. Nature communications 2 40467585
2025 Wnt5a suppresses colorectal cancer progression via TGF-β/NOTUM/OLFM4 axis in patient-derived organoids. Cell communication and signaling : CCS 1 40765051
2026 ARL6IP1 Inhibits Breast Cancer Tumor Progression by Targeting OLFM4 to Regulate Glycolysis. Combinatorial chemistry & high throughput screening 0 40444622
2026 OLFM4 orchestrates the immunosuppressive microenvironment and drives gallbladder cancer progression. Journal of cancer research and clinical oncology 0 41934482
2026 RPSA-OLFM4 axis governs neutrophil migration against bacterial infection and sepsis. Nature communications 0 42034613
2026 LRFN5 and OLFM4 in Acute Manic Episodes With Psychotic Features in Bipolar Disorder: A Case-Control Study in Türkiye. International journal of psychiatry in medicine 0 42068214
2026 Basal gland localization and focal distribution of OLFM4-expressing cells in increasing severity of gastric intestinal metaplasia. bioRxiv : the preprint server for biology 0 42239144
2022 Significance of differential expression of OLFM4 in the development of endometrial adenocarcinoma. Medicine 0 36451436

Missed literature

Know a paper Affinage missed for OLFM4? Flag it for the maintainers and the community.

No submissions yet.